Merck Reports Solid Second Quarter; Its Drug Pipeline Looks Promising
Merck reported solid second quarter results and indicated that progress in its pipeline remains strong. Though the firm will face patent expiration of its blockbuster Singulair in coming weeks, we think shares remain fairly valued.